Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06107231

WHNRC (Western Human Nutrition Research Center) Honey Study

The purpose of this research is to compare two snacks, one with honey and nuts and the other with sugar and nuts, on glucose levels before and after eating these snacks.

The investigators hypothesize that honey and nuts will have an additive effect on the reduction of postprandial glucose response. The investigators further hypothesize that consumption of honey paired with nuts will retain the benefit of sugar consumption in satiety and reduction of metabolic stress.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

18 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

USDA, ARS, Western Human Nutrition Research Center

Davis, California, 95616, United States

About this study

Consuming sugar creates a feeling of satiation, and may buffer metabolic stress. However, prolonged postprandial hyperglycemia has been identified as a potential risk factor in type 2 diabetes and cardiovascular disease. Nuts, which are recommended to be consumed as part of a Mediterranean diet, up to 2 servings per day, have been shown to dramatically reduce postprandial glucose response to carbohydrates. Additionally, honey, which is typically used as an added sugar within a Mediterranean diet pattern, has a lower glycemic index than table sugar and may result in a reduced postprandial glucose response relative to other nutritive sweeteners. However, it is not yet known whether honey can work additively with nuts to further reduce postprandial glucose response over the reduction caused by nuts alone.

Honey has been shown to produce equivalent or greater satiety to regular table sugar and there is some indication that honey can improve immediate/working memory. Therefore, combined consumption of honey and nuts may offer a way to maximize the benefits of carbohydrate consumption on satiety and metabolic stress reduction while minimizing its negative effects on metabolism. However, it is not yet known whether sugars contained in the more complex food matrix of honey, consumed together with a food like nuts can impact satiety and metabolic stress in the way that has been observed for sugar.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women must be pre-menopausal
  • Willing to consume snacks that contain honey, table sugar, and tree nuts

Exclusion criteria

  • Body Mass Index (BMI) <18.5 or >40
  • Allergies to tree nuts
  • Current medical diagnoses of chronic diseases including cardiovascular or pulmonary diseases, renal diseases, cancer, type 1 or type 2 diabetes, thyroid disease requiring medication, inflammatory or irritable bowel diseases, or those with recent major surgeries
  • No individuals who fall in to the vulnerable categories of adults including those unable to consent, pregnant women, children, or prisoners will be eligible for this study
  • Routinely taking medications known to affect glucose response.
  • Caffeine and alcohol use will not be excluded, but should be carefully reported by each subject.

Regarding female candidates:

  • Post-menopausal
  • Women who have been pregnant or nursing within the last 6 months or plan to become pregnant during the trial will be ineligible

Treatment and study plan

Honey

Other

Honey representing 7% of total energy (kilocalorie) needs (40-70 grams)

Sucrose

Other

Sucrose representing 7% of total energy (kilocalorie) needs (40-70 grams)

Honey plus almonds

Other

Honey representing 7% of total energy (kilocalorie) needs (40-70 grams) plus 1 ounce almonds (28 grams)

Sucrose plus almonds

Other

Sucrose representing 7% of total energy (kilocalorie) needs (40-70 grams) plus 1 ounce almonds (28 grams)

Primary outcomes

  1. Change in postprandial glucose response

    Time frame: Measured continuously over days 0-8 and 23-31

    Interstitial glucose response measured by a continuous glucose monitor

Secondary outcomes

  1. Change in Self-reported hunger

    Time frame: Fasting and 30, 60, and 90 min after consumption of standard breakfast on days 4, 8, 27, and 31

    Responses regarding hunger will be collected using a visual analog scale on a tablet with a 0-100 scale depicting the extremes (0= not at all to 100= extremely)

  2. Change in Self-reported fullness

    Time frame: Fasting and 30, 60, and 90 min after consumption of standard breakfast on days 4, 8, 27, and 31

    Responses regarding fullness will be collected using a visual analog scale on a tablet with a 0-100 scale depicting the extremes (0= not at all to 100= extremely)

  3. Change in Self-reported desire to eat

    Time frame: Fasting and 30, 60, and 90 min after consumption of standard breakfast on days 4, 8, 27, and 31

    Responses regarding desire to eat will be collected using a visual analog scale on a tablet with a 0-100 scale depicting the extremes (0= not at all to 100= extremely)

  4. Change in Self-reported satisfaction with snack

    Time frame: Fasting and 30, 60, and 90 min after consumption of standard breakfast on days 4, 8, 27, and 31

    Responses regarding satisfaction with snack will be collected using a visual analog scale on a tablet with a 0-100 scale depicting the extremes (0= not at all to 100= extremely)

  5. Change in Self-reported prospective consumption

    Time frame: Fasting and 30, 60, and 90 min after consumption of standard breakfast on days 4, 8, 27, and 31

    Responses regarding prospective consumption will be collected using a visual analog scale on a tablet with a 0-100 scale depicting the extremes (0= not at all to 100= extremely)

  6. Change in Self-reported nausea

    Time frame: Fasting and 30, 60, and 90 min after consumption of standard breakfast on days 4, 8, 27, and 31

    Responses regarding nausea will be collected using a visual analog scale on a tablet with a 0-100 scale depicting the extremes (0= not at all to 100= extremely)

  7. Change in Cognitive testing for Spatial Working Memory

    Time frame: Days 4, 8, 27, and 31

    Cambridge Neuropsychological Test Automated battery (CANTAB) software will be used to assess Spatial Working Memory (SWM)

  8. Change in Cognitive testing for Paired Associates Learning

    Time frame: Days 4, 8, 27, and 31

    CANTAB software will be used to assess Paired Associates Learning (PAL)

  9. Change in Cognitive testing for Rapid Visual Processing

    Time frame: Days 4, 8, 27, and 31

    CANTAB software will be used to assess Rapid Visual Processing (RVP)

  10. Change in Salivary cortisol

    Time frame: Day 0 and 23 fasting only. Days 4, 8, 27, and 31 at fasting, 30, 60 and 90 min after consumption of snack provided in standard breakfast

    Metabolic stress will be analyzed by measuring cortisol in saliva samples

  11. Assessment of Fasted Salivary Estradiol

    Time frame: Days 0, 4, 8, 23, 27,and 31 at fasting only

    Passive drool will be assayed for estradiol as they impact metabolic stress throughout study days

  12. Assessment of Fasted Salivary Progesterone

    Time frame: Days 0, 4, 8, 23, 27,and 31 at fasting only

    Passive drool will be assayed for progesterone as they impact metabolic stress throughout study days

  13. Change in Stool marker of inflammation

    Time frame: Stool collected on study days 0, 4, 8, 23, 27, and 31

    Fecal calprotectin measured in stool samples

  14. Change in Stool bacterial metagenomics

    Time frame: Stool collected on study days 0, 4, 8, 23, 27, and 31

    Honey responsive genes identified by metagenomics

  15. Change in Dietary Intake

    Time frame: Days 1-3, 5-7, 24-26, and 28-30

    Food records collected using Automated Multi-pass Method (AMPM) on the platform ASA24

Sponsors and collaborators

Lead sponsor

USDA, Western Human Nutrition Research Center

Fed

Collaborators

  • National Honey Board

Registry information

Important dates

Study start
2024
Primary completion
2025
Study completion
2026
First posted
Oct 30, 2023
Registry last updated
May 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.